Postmenopausal Estrogen Use and Invasive versus in situ Breast Cancer Risk
To examine the effect of cancer histopathology on the relationship between estrogen-replacement therapy (ERT) use and breast cancer risk, we performed a case-control study of 109 postmenopausal women 45 years or older with in situ or invasive breast cancer matched to 545 controls. When in situ and i...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical epidemiology 1998-12, Vol.51 (12), p.1277-1283 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1283 |
|---|---|
| container_issue | 12 |
| container_start_page | 1277 |
| container_title | Journal of clinical epidemiology |
| container_volume | 51 |
| creator | Henrich, Janet B. Kornguth, Phyllis J. Viscoli, Catherine M. Horwitz, Ralph I. |
| description | To examine the effect of cancer histopathology on the relationship between estrogen-replacement therapy (ERT) use and breast cancer risk, we performed a case-control study of 109 postmenopausal women 45 years or older with
in situ or invasive breast cancer matched to 545 controls. When
in situ and invasive tumors were combined, the overall odds ratio (OR) describing the association between ERT use and breast cancer risk was not statistically significantly elevated (adjusted OR = 1.48, 95% confidence interval [CI] = 0.89–2.47). When the analyses were confined to women with invasive disease, risk estimates were uniformly higher (adjusted OR = 1.85, 95% CI = 1.00–3.45). In contrast, the overall estimate for the relationship between ERT use and
in situ breast cancer was close to 1 (adjusted OR = 1.08, 95% CI = 0.42–2.77). The positive association between ERT use and invasive breast cancer we observed, and the lack of association in women with
in situ disease, may represent a distinct biological difference or may be related to the small sample size of our study. |
| doi_str_mv | 10.1016/S0895-4356(98)00116-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17138235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0895435698001164</els_id><sourcerecordid>17138235</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-2d4b22fee57cb896137d321446ca8bf8a7805b06e3aa710797436031105566c83</originalsourceid><addsrcrecordid>eNqF0E1P3DAQgGGrApVl6U9o5QOq6CHgieOPnKp2RfkQEqgtZ8txJpVLNlk8yUr8ewK7Am6crJEee6yXsc8gjkGAPvkjbKmyQip9VNpvQgDorPjAZmCNzVSZww6bvZA9tk_0f0JGGPWR7YEQVttczNjlTU_DErt-5UfyLT-lIfX_sOO3hNx3Nb_o1p7iGvkaE43EY8cpDiP_mdDTwBe-C5j470h3B2y38S3hp-05Z7e_Tv8uzrOr67OLxY-rLBTaDlleF1WeN4jKhMqWGqSpZQ5FoYO3VWO9sUJVQqP03oAwpSmkFhJAKKV1sHLOvm7eXaX-fkQa3DJSwLb1HfYjOTAgbS7VBNUGhtQTJWzcKsWlTw8OhHuK6J4juqdCrrTuOeI0zdmX7YKxWmL95tam2gQOt8BT8G2TpgiRXp0GrYp8Yt83DKca64jJUYg49apjwjC4uo_v_OQRma-Mbg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17138235</pqid></control><display><type>article</type><title>Postmenopausal Estrogen Use and Invasive versus in situ Breast Cancer Risk</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Henrich, Janet B. ; Kornguth, Phyllis J. ; Viscoli, Catherine M. ; Horwitz, Ralph I.</creator><creatorcontrib>Henrich, Janet B. ; Kornguth, Phyllis J. ; Viscoli, Catherine M. ; Horwitz, Ralph I.</creatorcontrib><description>To examine the effect of cancer histopathology on the relationship between estrogen-replacement therapy (ERT) use and breast cancer risk, we performed a case-control study of 109 postmenopausal women 45 years or older with
in situ or invasive breast cancer matched to 545 controls. When
in situ and invasive tumors were combined, the overall odds ratio (OR) describing the association between ERT use and breast cancer risk was not statistically significantly elevated (adjusted OR = 1.48, 95% confidence interval [CI] = 0.89–2.47). When the analyses were confined to women with invasive disease, risk estimates were uniformly higher (adjusted OR = 1.85, 95% CI = 1.00–3.45). In contrast, the overall estimate for the relationship between ERT use and
in situ breast cancer was close to 1 (adjusted OR = 1.08, 95% CI = 0.42–2.77). The positive association between ERT use and invasive breast cancer we observed, and the lack of association in women with
in situ disease, may represent a distinct biological difference or may be related to the small sample size of our study.</description><identifier>ISSN: 0895-4356</identifier><identifier>EISSN: 1878-5921</identifier><identifier>DOI: 10.1016/S0895-4356(98)00116-4</identifier><identifier>PMID: 10086820</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - epidemiology ; Breast Neoplasms - pathology ; Carcinoma in Situ - diagnosis ; Carcinoma in Situ - epidemiology ; Carcinoma in Situ - pathology ; Case-Control Studies ; clinical epidemiology ; Drug toxicity and drugs side effects treatment ; estrogen replacement therapy ; Estrogen Replacement Therapy - adverse effects ; Female ; Humans ; Logistic Models ; Mammography ; Medical sciences ; Middle Aged ; Neoplasm Invasiveness - diagnosis ; Neoplasm Invasiveness - pathology ; Odds Ratio ; Pharmacology. Drug treatments ; Postmenopausal ; Postmenopause ; Toxicity: urogenital system</subject><ispartof>Journal of clinical epidemiology, 1998-12, Vol.51 (12), p.1277-1283</ispartof><rights>1998 Elsevier Science Inc.</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-2d4b22fee57cb896137d321446ca8bf8a7805b06e3aa710797436031105566c83</citedby><cites>FETCH-LOGICAL-c468t-2d4b22fee57cb896137d321446ca8bf8a7805b06e3aa710797436031105566c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0895-4356(98)00116-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1616542$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10086820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Henrich, Janet B.</creatorcontrib><creatorcontrib>Kornguth, Phyllis J.</creatorcontrib><creatorcontrib>Viscoli, Catherine M.</creatorcontrib><creatorcontrib>Horwitz, Ralph I.</creatorcontrib><title>Postmenopausal Estrogen Use and Invasive versus in situ Breast Cancer Risk</title><title>Journal of clinical epidemiology</title><addtitle>J Clin Epidemiol</addtitle><description>To examine the effect of cancer histopathology on the relationship between estrogen-replacement therapy (ERT) use and breast cancer risk, we performed a case-control study of 109 postmenopausal women 45 years or older with
in situ or invasive breast cancer matched to 545 controls. When
in situ and invasive tumors were combined, the overall odds ratio (OR) describing the association between ERT use and breast cancer risk was not statistically significantly elevated (adjusted OR = 1.48, 95% confidence interval [CI] = 0.89–2.47). When the analyses were confined to women with invasive disease, risk estimates were uniformly higher (adjusted OR = 1.85, 95% CI = 1.00–3.45). In contrast, the overall estimate for the relationship between ERT use and
in situ breast cancer was close to 1 (adjusted OR = 1.08, 95% CI = 0.42–2.77). The positive association between ERT use and invasive breast cancer we observed, and the lack of association in women with
in situ disease, may represent a distinct biological difference or may be related to the small sample size of our study.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma in Situ - diagnosis</subject><subject>Carcinoma in Situ - epidemiology</subject><subject>Carcinoma in Situ - pathology</subject><subject>Case-Control Studies</subject><subject>clinical epidemiology</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>estrogen replacement therapy</subject><subject>Estrogen Replacement Therapy - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Mammography</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness - diagnosis</subject><subject>Neoplasm Invasiveness - pathology</subject><subject>Odds Ratio</subject><subject>Pharmacology. Drug treatments</subject><subject>Postmenopausal</subject><subject>Postmenopause</subject><subject>Toxicity: urogenital system</subject><issn>0895-4356</issn><issn>1878-5921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0E1P3DAQgGGrApVl6U9o5QOq6CHgieOPnKp2RfkQEqgtZ8txJpVLNlk8yUr8ewK7Am6crJEee6yXsc8gjkGAPvkjbKmyQip9VNpvQgDorPjAZmCNzVSZww6bvZA9tk_0f0JGGPWR7YEQVttczNjlTU_DErt-5UfyLT-lIfX_sOO3hNx3Nb_o1p7iGvkaE43EY8cpDiP_mdDTwBe-C5j470h3B2y38S3hp-05Z7e_Tv8uzrOr67OLxY-rLBTaDlleF1WeN4jKhMqWGqSpZQ5FoYO3VWO9sUJVQqP03oAwpSmkFhJAKKV1sHLOvm7eXaX-fkQa3DJSwLb1HfYjOTAgbS7VBNUGhtQTJWzcKsWlTw8OhHuK6J4juqdCrrTuOeI0zdmX7YKxWmL95tam2gQOt8BT8G2TpgiRXp0GrYp8Yt83DKca64jJUYg49apjwjC4uo_v_OQRma-Mbg</recordid><startdate>19981201</startdate><enddate>19981201</enddate><creator>Henrich, Janet B.</creator><creator>Kornguth, Phyllis J.</creator><creator>Viscoli, Catherine M.</creator><creator>Horwitz, Ralph I.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U1</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19981201</creationdate><title>Postmenopausal Estrogen Use and Invasive versus in situ Breast Cancer Risk</title><author>Henrich, Janet B. ; Kornguth, Phyllis J. ; Viscoli, Catherine M. ; Horwitz, Ralph I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-2d4b22fee57cb896137d321446ca8bf8a7805b06e3aa710797436031105566c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma in Situ - diagnosis</topic><topic>Carcinoma in Situ - epidemiology</topic><topic>Carcinoma in Situ - pathology</topic><topic>Case-Control Studies</topic><topic>clinical epidemiology</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>estrogen replacement therapy</topic><topic>Estrogen Replacement Therapy - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Mammography</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness - diagnosis</topic><topic>Neoplasm Invasiveness - pathology</topic><topic>Odds Ratio</topic><topic>Pharmacology. Drug treatments</topic><topic>Postmenopausal</topic><topic>Postmenopause</topic><topic>Toxicity: urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henrich, Janet B.</creatorcontrib><creatorcontrib>Kornguth, Phyllis J.</creatorcontrib><creatorcontrib>Viscoli, Catherine M.</creatorcontrib><creatorcontrib>Horwitz, Ralph I.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of clinical epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henrich, Janet B.</au><au>Kornguth, Phyllis J.</au><au>Viscoli, Catherine M.</au><au>Horwitz, Ralph I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postmenopausal Estrogen Use and Invasive versus in situ Breast Cancer Risk</atitle><jtitle>Journal of clinical epidemiology</jtitle><addtitle>J Clin Epidemiol</addtitle><date>1998-12-01</date><risdate>1998</risdate><volume>51</volume><issue>12</issue><spage>1277</spage><epage>1283</epage><pages>1277-1283</pages><issn>0895-4356</issn><eissn>1878-5921</eissn><abstract>To examine the effect of cancer histopathology on the relationship between estrogen-replacement therapy (ERT) use and breast cancer risk, we performed a case-control study of 109 postmenopausal women 45 years or older with
in situ or invasive breast cancer matched to 545 controls. When
in situ and invasive tumors were combined, the overall odds ratio (OR) describing the association between ERT use and breast cancer risk was not statistically significantly elevated (adjusted OR = 1.48, 95% confidence interval [CI] = 0.89–2.47). When the analyses were confined to women with invasive disease, risk estimates were uniformly higher (adjusted OR = 1.85, 95% CI = 1.00–3.45). In contrast, the overall estimate for the relationship between ERT use and
in situ breast cancer was close to 1 (adjusted OR = 1.08, 95% CI = 0.42–2.77). The positive association between ERT use and invasive breast cancer we observed, and the lack of association in women with
in situ disease, may represent a distinct biological difference or may be related to the small sample size of our study.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>10086820</pmid><doi>10.1016/S0895-4356(98)00116-4</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0895-4356 |
| ispartof | Journal of clinical epidemiology, 1998-12, Vol.51 (12), p.1277-1283 |
| issn | 0895-4356 1878-5921 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17138235 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Aged, 80 and over Biological and medical sciences breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - epidemiology Breast Neoplasms - pathology Carcinoma in Situ - diagnosis Carcinoma in Situ - epidemiology Carcinoma in Situ - pathology Case-Control Studies clinical epidemiology Drug toxicity and drugs side effects treatment estrogen replacement therapy Estrogen Replacement Therapy - adverse effects Female Humans Logistic Models Mammography Medical sciences Middle Aged Neoplasm Invasiveness - diagnosis Neoplasm Invasiveness - pathology Odds Ratio Pharmacology. Drug treatments Postmenopausal Postmenopause Toxicity: urogenital system |
| title | Postmenopausal Estrogen Use and Invasive versus in situ Breast Cancer Risk |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A05%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postmenopausal%20Estrogen%20Use%20and%20Invasive%20versus%20in%20situ%20Breast%20Cancer%20Risk&rft.jtitle=Journal%20of%20clinical%20epidemiology&rft.au=Henrich,%20Janet%20B.&rft.date=1998-12-01&rft.volume=51&rft.issue=12&rft.spage=1277&rft.epage=1283&rft.pages=1277-1283&rft.issn=0895-4356&rft.eissn=1878-5921&rft_id=info:doi/10.1016/S0895-4356(98)00116-4&rft_dat=%3Cproquest_cross%3E17138235%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17138235&rft_id=info:pmid/10086820&rft_els_id=S0895435698001164&rfr_iscdi=true |